ADMA Biologics (ADMA) Tops Q4 EPS by 31c, Offers Guidance

ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of $0.46, $0.31 better than the analyst estimate of $0.15. Revenue for the quarter came in at $117.5 million versus the consensus estimate of $113.4 million.

GUIDANCE:

ADMA Biologics sees FY2025 revenue of $490 million.

ADMA Biologics sees FY2026 revenue of $605 million.

Financial Guidance:

• FY 2025 and 2026 total revenue increased to more than $490 million and $605 million, respectively
• FY 2025 and 2026 Adjusted Net Income increased to more than $175 million and $235 million, respectively
• FY 2025 and 2026 Adjusted EBITDA increased to more than $225 million and $305 million, respectively
• Greater than $1 billion of total annual revenue expected to be achieved prior to 2030, with anticipated outsized earnings growth from current margin levels

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (F
• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• GitLab updates consumption revenue metric, CRR surpasses $20M